SM patients: prognostic factors for PFS and OS (n = 34)
| Disease features . | n . | Univariate analysis . | |||
|---|---|---|---|---|---|
| PFS, y . | OS, y . | ||||
| Median (range) . | P . | Median (range) . | P . | ||
| Clinical and laboratory features | |||||
| Diagnosis | |||||
| Nonadvanced SM | 12 | 14 (2-32) | NS | NR (3-48) | NS |
| Advanced SM | 22 | 11 (1-18) | 11 (1-18) | ||
| Age at diagnosis, y | |||||
| <60 | 23 | 14 (1-32) | NS | NR (1-48) | NS |
| ≥60 | 11 | 5 (1-10) | 6 (1-12) | ||
| Skin lesions | |||||
| No | 10 | 4 (1-6) | NS | 6 (1-13) | 0.02 |
| Yes | 24 | 14 (1-32) | NR (3-48) | ||
| BM MCs, % | |||||
| <1 | 14 | 5 (1-19) | NS | 11 (1-19) | NS |
| ≥1 | 18 | 14 (1-32) | NR (1-48) | ||
| sBT, µg/L | |||||
| <200 | 10 | 15 (1-17) | NS | NR (1-17) | NS |
| ≥200 | 22 | 6 (1-32) | NR (1-48) | ||
| Hemoglobin, g/L | |||||
| <100 | 5 | 3 (1-6) | NS | 4 (1-7) | .001 |
| ≥100 | 29 | 14 (1-32) | NR (1-48) | ||
| Platelets, ×109/L | |||||
| <100 | 11 | 4 (1-15) | .03 | 4 (1-17) | .04 |
| ≥100 | 23 | 14 (1-32) | NR (1-48) | ||
| β2-microglobulin, µg/mL | |||||
| <2.5 | 7 | NR (2-18) | NS | NR (3-17) | .04 |
| ≥2.5 | 20 | 5 (1-32) | 10 (1-48) | ||
| SAP, U/L | |||||
| <150 | 16 | 32 (2-32) | .01 | NR (3-48) | .01 |
| ≥150 | 14 | 4 (1-30) | 10 (1-39) | ||
| Splenomegaly | |||||
| No | 11 | 30 (1-30) | .04 | NR (1-39) | NS |
| Yes | 23 | 5 (1-32) | 11 (1-48) | ||
| Hepatomegaly | |||||
| No | 16 | 15 (1-19) | NS | NR (1-19) | NS |
| Yes | 18 | 5 (1-32) | 11 (1-48) | ||
| Number of nonsynonymous coding genetic variants | |||||
| Total somatic mutations | |||||
| 0 | 9 | 30 (2-32) | .02 | NR (3-48) | .005 |
| ≥1 | 11 | 4 (1-15) | 6 (2-17) | ||
| MC restricted | |||||
| 0 | 15 | 14 (1-32) | NS | NR (2-48) | NS |
| ≥1 | 5 | 6 (1-15) | 7 (6-17) | ||
| Multilineal | |||||
| 0 | 10 | 30 (2-32) | .009 | NR (3-48) | .001 |
| ≥1 | 10 | 3 (1-10) | 6 (2-10) | ||
| Germline genetic variants | |||||
| <3 | 17 | 14 (1-32) | .016 | NR (4-48) | .004 |
| ≥3 | 3 | 3 (1-4) | 4 (2-10) | ||
| Total genetic variants | |||||
| <3 | 11 | 30 (2-32) | .002 | NR (3-48) | <.001 |
| ≥3 | 9 | 3 (1-6) | 6 (2-10) | ||
| Gene panel mutational status | |||||
| S/A/R | |||||
| WT | 23 | 15 (2-32) | <.001 | NR (3-48) | .002 |
| Mutated | 11 | 2 (1-4) | 6 (1-13) | ||
| S/A/R/E | |||||
| WT | 19 | 30 (2-32) | <.001 | NR (3-48) | <.001 |
| Mutated | 15 | 3 (1-6) | 6 (1-13) | ||
| Disease features . | n . | Univariate analysis . | |||
|---|---|---|---|---|---|
| PFS, y . | OS, y . | ||||
| Median (range) . | P . | Median (range) . | P . | ||
| Clinical and laboratory features | |||||
| Diagnosis | |||||
| Nonadvanced SM | 12 | 14 (2-32) | NS | NR (3-48) | NS |
| Advanced SM | 22 | 11 (1-18) | 11 (1-18) | ||
| Age at diagnosis, y | |||||
| <60 | 23 | 14 (1-32) | NS | NR (1-48) | NS |
| ≥60 | 11 | 5 (1-10) | 6 (1-12) | ||
| Skin lesions | |||||
| No | 10 | 4 (1-6) | NS | 6 (1-13) | 0.02 |
| Yes | 24 | 14 (1-32) | NR (3-48) | ||
| BM MCs, % | |||||
| <1 | 14 | 5 (1-19) | NS | 11 (1-19) | NS |
| ≥1 | 18 | 14 (1-32) | NR (1-48) | ||
| sBT, µg/L | |||||
| <200 | 10 | 15 (1-17) | NS | NR (1-17) | NS |
| ≥200 | 22 | 6 (1-32) | NR (1-48) | ||
| Hemoglobin, g/L | |||||
| <100 | 5 | 3 (1-6) | NS | 4 (1-7) | .001 |
| ≥100 | 29 | 14 (1-32) | NR (1-48) | ||
| Platelets, ×109/L | |||||
| <100 | 11 | 4 (1-15) | .03 | 4 (1-17) | .04 |
| ≥100 | 23 | 14 (1-32) | NR (1-48) | ||
| β2-microglobulin, µg/mL | |||||
| <2.5 | 7 | NR (2-18) | NS | NR (3-17) | .04 |
| ≥2.5 | 20 | 5 (1-32) | 10 (1-48) | ||
| SAP, U/L | |||||
| <150 | 16 | 32 (2-32) | .01 | NR (3-48) | .01 |
| ≥150 | 14 | 4 (1-30) | 10 (1-39) | ||
| Splenomegaly | |||||
| No | 11 | 30 (1-30) | .04 | NR (1-39) | NS |
| Yes | 23 | 5 (1-32) | 11 (1-48) | ||
| Hepatomegaly | |||||
| No | 16 | 15 (1-19) | NS | NR (1-19) | NS |
| Yes | 18 | 5 (1-32) | 11 (1-48) | ||
| Number of nonsynonymous coding genetic variants | |||||
| Total somatic mutations | |||||
| 0 | 9 | 30 (2-32) | .02 | NR (3-48) | .005 |
| ≥1 | 11 | 4 (1-15) | 6 (2-17) | ||
| MC restricted | |||||
| 0 | 15 | 14 (1-32) | NS | NR (2-48) | NS |
| ≥1 | 5 | 6 (1-15) | 7 (6-17) | ||
| Multilineal | |||||
| 0 | 10 | 30 (2-32) | .009 | NR (3-48) | .001 |
| ≥1 | 10 | 3 (1-10) | 6 (2-10) | ||
| Germline genetic variants | |||||
| <3 | 17 | 14 (1-32) | .016 | NR (4-48) | .004 |
| ≥3 | 3 | 3 (1-4) | 4 (2-10) | ||
| Total genetic variants | |||||
| <3 | 11 | 30 (2-32) | .002 | NR (3-48) | <.001 |
| ≥3 | 9 | 3 (1-6) | 6 (2-10) | ||
| Gene panel mutational status | |||||
| S/A/R | |||||
| WT | 23 | 15 (2-32) | <.001 | NR (3-48) | .002 |
| Mutated | 11 | 2 (1-4) | 6 (1-13) | ||
| S/A/R/E | |||||
| WT | 19 | 30 (2-32) | <.001 | NR (3-48) | <.001 |
| Mutated | 15 | 3 (1-6) | 6 (1-13) | ||
NR, not reached; NS, not statistically significant (P > .05); SAP, serum alkaline phosphatase; WT, wild-type.